Last reviewed 2026-04-23 · How we verify

Etoposide-Cisplatin combined chemotherapy

Etoposide-Cisplatin combined chemotherapy is a Combination chemotherapy Small molecule drug developed by Sumitomo Pharma (Suzhou) Co., Ltd.. It is currently in Phase 3 development for Small cell lung cancer, Other solid tumors (specific indications in Phase 3 trial unknown).

Etoposide and cisplatin work together as a combination chemotherapy regimen that kills cancer cells by damaging DNA through different mechanisms.

Etoposide and cisplatin work together as a combination chemotherapy regimen that kills cancer cells by damaging DNA through different mechanisms. Used for Small cell lung cancer, Other solid tumors (specific indications in Phase 3 trial unknown).

At a glance

Mechanism of action

Etoposide is a topoisomerase II inhibitor that prevents DNA repair and causes double-strand breaks, while cisplatin is a platinum-based alkylating agent that cross-links DNA strands and prevents replication. Together, they provide synergistic cytotoxic effects against rapidly dividing cancer cells. This combination is particularly effective against small cell lung cancer and other solid tumors.

Approved indications

• Small cell lung cancer
• Other solid tumors (specific indications in Phase 3 trial unknown)

Common side effects

• Myelosuppression (neutropenia, thrombocytopenia, anemia)
• Nausea and vomiting
• Nephrotoxicity
• Ototoxicity
• Peripheral neuropathy
• Alopecia

Key clinical trials

• Durvalumab as Consolidation for Patients LS-SCLC (PHASE2)
• Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma (PHASE1, PHASE2)
• Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer (PHASE2)
• Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (PHASE2)
• Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors (PHASE2)
• A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma (PHASE1, PHASE2)
• Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer (PHASE2)
• Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Etoposide-Cisplatin combined chemotherapy CI brief — competitive landscape report
• Etoposide-Cisplatin combined chemotherapy updates RSS · CI watch RSS
• Sumitomo Pharma (Suzhou) Co., Ltd. portfolio CI

Frequently asked questions about Etoposide-Cisplatin combined chemotherapy

Related

• Drug class: All Combination chemotherapy drugs
• Manufacturer: Sumitomo Pharma (Suzhou) Co., Ltd. — full pipeline
• Therapeutic area: All drugs in Oncology
• Indication: Drugs for Small cell lung cancer
• Indication: Drugs for Other solid tumors (specific indications in Phase 3 trial unknown)